2003-05-01
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group
Publication
Publication
European Journal of Cancer , Volume 39 - Issue 8 p. 1141- 1143
30 patients with advanced ovarian cancer, all platinum pretreated, were treated with an induction cycle of fotemustine. Maintenance therapy was given to 6 patients. No objective response was observed among the 21 evaluable patients. The main toxicities were gastrointestinal, with grade 3 nausea and vomiting reported in 40% of the patients, and haematological, with grade 4 leucopenia reported in 2 patients and grade 4 thrombocytopenia in 5 patients. Therefore, no role has been demonstrated in our cohort for the use of fotemustine, a nitrosourea, in pretreated ovarian cancer.
| Additional Metadata | |
|---|---|
| , , , | |
| doi.org/10.1016/S0959-8049(03)00198-9, hdl.handle.net/1765/74085 | |
| European Journal of Cancer | |
| Organisation | Department of Gynaecology & Obstetrics |
|
Aapro, M., van Wijk, F., van der Burg, M., Ten Bokkel Huinink, W., Vergote, I., Guastalla, J. P., … Vermorken, J. (2003). Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group. European Journal of Cancer, 39(8), 1141–1143. doi:10.1016/S0959-8049(03)00198-9 |
|